Olodaterol (formerly known as BI-1744; BI1744; STRIVERDI RESPIMAT) is a ultra-long acting beta-adrenoceptor agonist approved in 2014 for use as an inhalation for treating patients with chronic obstructive pulmonary disease (COPD) It was developed and manufactured by Boehringer-Ingelheim. Olodaterol was approved by FDA in 2014 for the treatment of chronic obstructive pulmonary disease.

纯度：≥98%

CAS：868049-49-4